Literature DB >> 17157129

Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.

Pierre Paré1, James Gray, Sy Lam, Robert Balshaw, Shideh Khorasheh, Martin Barbeau, Suzanne Kelly, Christopher R McBurney.   

Abstract

BACKGROUND: Abdominal pain/discomfort, bloating, and constipation are gastrointestinal dysmotility and sensory symptoms associated with irritable bowel syndrome (IBS). No studies have followed patients with IBS symptoms for 1 year under conditions of routine clinical practice to assess prospectively the impact of treatments on health outcomes.
OBJECTIVE: The objective of this ongoing, naturalistic study is to assess the long-term impact of IBS treatments on quality of life (QOL), work productivity, and resource utilization. This report describes the baseline characteristics and patterns of care of the patients enrolled in this study.
METHODS: Patients with physician-diagnosed IBS symptoms were enrolled from 147 physician sites across Canada between May 4, 2004, and March 31, 2005. Clinical data were collected at baseline and at the end of the 12-month follow-up (patients were followed for 1 year between May 4, 2005, and March 31, 2006). Patient-reported outcomes were collected at baseline and at months 1, 2, 6, 9, and 12. Health-related QOL, health status, and work productivity were assessed with the IBS-QOL, a 5-item EuroQol descriptive system, and Work Productivity and Activity Impairment questionnaires, respectively. A resource utilization questionnaire elicited information on physician; visits, treatments, and procedures. Baseline data are reported here.
RESULTS: Data were obtained from 1555 patients; 85.1% (1320/1552) were women. Patients had a mean (SD) age of 45.8 (15.0) years and mean (SD) duration of IBS symptoms of 11.4 (11.5) years. Self-reported bowel patterns were predominantly constipation (41.0%, 587/1433) and constipation alternating with diarrhea (39.4%, 564/1433); 60.3% (938/1555) of subjects used > or =3 IBS treatments in the previous 4 weeks. Approximately 50% of all patients reported distress "quite a bit or "extremely" for abdominal pain, gas, bloating, and constipation. The mean overall IBS-QOL score (0-100 scale, with 0 indicating poor QOL) was 66.3; food avoidance (51.8) and health worry (59.3) were the most serious concerns. Patients reported 5.6% work absenteeism, 31.4% presenteeism, and 34.6% overall work productivity loss, equivalent to 13.8 hours lost productivity per 40-hour workweek.
CONCLUSIONS: The baseline data from this ongoing, prospective, naturalistic study are consistent with previous findings that suggested significant use of health care resources with concomitant low QOL and decreased work productivity in patients with IBS symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 17157129     DOI: 10.1016/j.clinthera.2006.10.010

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  65 in total

Review 1.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

2.  Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities.

Authors:  Antonio M Scanu; Tim J Bull; Sara Cannas; Jeremy D Sanderson; Leonardo A Sechi; Giuseppe Dettori; Stefania Zanetti; John Hermon-Taylor
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

3.  I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Authors:  Vicente Lorenzo-Zúñiga; Elba Llop; Cristina Suárez; Beatriz Alvarez; Luis Abreu; Jordi Espadaler; Jordi Serra
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations.

Authors:  Michelle G Craske; Kate B Wolitzky-Taylor; Jennifer Labus; Stephen Wu; Michael Frese; Emeran A Mayer; Bruce D Naliboff
Journal:  Behav Res Ther       Date:  2011-04-19

5.  Trauma history and risk of the irritable bowel syndrome in women veterans.

Authors:  D L White; L S Savas; K Daci; R Elserag; D P Graham; S J Fitzgerald; S L Smith; G Tan; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2010-06-04       Impact factor: 8.171

6.  Perceived health is partially associated with the symptomatological profile in patients with benign and severe conditions: the case of congenital heart disease.

Authors:  D Schoormans; M A G Sprangers; W Budts; B J M Mulder; S Apers; P Moons
Journal:  Qual Life Res       Date:  2012-07-31       Impact factor: 4.147

7.  Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort.

Authors:  Brennan Spiegel; Lucinda Harris; Susan Lucak; Emeran Mayer; Bruce Naliboff; Roger Bolus; Eric Esrailian; William D Chey; Anthony Lembo; Hetal Karsan; Kirsten Tillisch; Gareth Dulai; Jennifer Talley; Lin Chang
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

Review 8.  The burden of IBS: looking at metrics.

Authors:  Brennan M R Spiegel
Journal:  Curr Gastroenterol Rep       Date:  2009-08

9.  Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood.

Authors:  Marloes E J Bongers; Marc A Benninga; Heleen Maurice-Stam; Martha A Grootenhuis
Journal:  Health Qual Life Outcomes       Date:  2009-03-02       Impact factor: 3.186

10.  Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study.

Authors:  Javier P Gisbert; Alun Cooper; Dimitrios Karagiannis; Jan Hatlebakk; Lars Agréus; Helmut Jablonowski; Javier Nuevo
Journal:  Health Qual Life Outcomes       Date:  2009-10-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.